Melanotan 2 Peptide

The shortcut version of the tanning peptide, and the one medicine abandoned.

Melanotan 2 is a cyclic seven amino acid analogue of alpha melanocyte stimulating hormone that acts as a non-selective agonist at melanocortin receptors including MC1R, MC3R and MC4R. It was never taken through clinical development by any sponsor, is approved in no country, and its human literature consists largely of case reports describing adverse events.

Same family as the approved implant. Opposite biography.

Melanotan-2's a shortened cyclic analogue of alpha-MSH: more potent, less selective, and dropped by legitimate development decades ago.

Think of two cousins from the same Arizona lab in the 1980s. One finished school, got the diploma, and has an FDA label with monitoring requirements on it. The other one's the one your buddy knows a guy for.

The cyclic structure that makes it potent also makes it promiscuous across the melanocortin family, hitting departments its approved sibling was chosen specifically to avoid. Which is exactly why one sibling's got a drug label and the other's got case reports.

The difference between MT-1 and MT-2 is the difference between selectivity and reach, and the file below shows you what reach costs.

Less selective than its approved sibling, and the extra receptors are the problem.

Recall that the melanocortin family runs pigmentation, appetite and arousal signalling through related receptors.

MT-2's cyclic structure grips across all of them. It's a master key, and a master key opens the doors you wanted locked too.

Its arousal-signalling activity is literally how PT-141 got discovered, as a breakdown product of this molecule during trials that were then pointed somewhere else.

Here's the honest part.

A molecule can be potent, interesting and abandoned for cause all at once. The abandonment wasn't an accident of funding. Selectivity was the reason, and it's the whole reason.

The human literature is mostly case reports of things going wrong.

The published human record on MT-2 has an unusual shape, and the shape is the story.

There's a handful of small trials from the 1990s and 2000s, before development stopped. What's piled up since is case reports, and case reports in medicine are how bad outcomes get written down. They're the incident log at the front desk, not the brochure.

No approval anywhere, no sponsor, and no safety programme watching the grey market that actually uses it.

We're not gonna dress it up. Case reports don't have a denominator, so nobody can tell you how often any of this happens. They can tell you it's happened, and that clinicians thought it was worth writing up.

The approved sibling proves this family can make a real medicine. This molecule is the version of the story where nobody finished the work, and the case-report literature is what unfinished looks like in humans.

Same day out of British Columbia. Our building, our cold packs, our people, and nothing sitting in a customs queue while you refresh a tracking page.

Then into the fridge. Keep it cold and keep it dark. Sealed and freeze-dried it handles a rough trip without ice. Once it lands, fridge.

The case literature is the safety data. There is no trial safety profile for this compound because there was never a trial. What exists instead are published case reports including melanoma and changes in existing moles, rhabdomyolysis, and posterior reversible encephalopathy syndrome. We would rather you read that here than not at all.